Invivyd (NASDAQ:IVVD) Insider Sells $15,477.00 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 18,425 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total transaction of $15,477.00. Following the completion of the transaction, the insider owned 168,937 shares of the company’s stock, valued at $141,907.08. This trade represents a 9.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

• On Monday, August 17th, Julie Green sold 22,355 shares of Invivyd stock. The stock was sold at an average price of $0.72, for a total value of $16,095.60.

Invivyd Stock Performance

Shares of IVVD opened at $0.95 on Friday. The firm has a market capitalization of $280.26 million, a price-to-earnings ratio of -2.88 and a beta of 0.71. The business’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $1.22. Invivyd, Inc. has a 52 week low of $0.48 and a 52 week high of $3.07.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. As a group, research analysts forecast that Invivyd, Inc. will post -0.51 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on IVVD shares. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Finally, BTIG Research reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Courier Capital LLC acquired a new stake in shares of Invivyd during the fourth quarter worth $25,000. Bronte Capital Management Pty Ltd. acquired a new stake in shares of Invivyd during the fourth quarter worth about $27,000. DRW Securities LLC acquired a new stake in Invivyd during the 4th quarter worth approximately $27,000. ProShare Advisors LLC acquired a new stake in shares of Invivyd during the fourth quarter worth $30,000. Finally, State of Wyoming bought a new stake in shares of Invivyd in the fourth quarter valued at about $30,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.